Expand MNKD Menu
MNKD MENU

MNKD Latest Press Releases

-- August 5, 2026 --

MannKind Reports Second Quarter 2026 Financial Results and Provides Business Update Globe Newswire 4:01 PM

-- July 29, 2026 --

MannKind Reports Positive Phase 1b INFLO-1 Results, Demonstrating Safety and Tolerability of Nintedanib DPI and Clinical Validation of Its DPI Technology in IPF Globe Newswire 6:30 AM

-- July 28, 2026 --

MannKind to Report Second Quarter Financial Results and Host Conference Call on August 5, 2026 Globe Newswire 4:01 PM

-- July 24, 2026 --

MannKind Announces $50 Million Private Placement Globe Newswire 6:35 AM
MannKind Announces FDA Approval of Furoscix ReadyFlow , the First and Only Autoinjector Delivering IV-Equivalent Diuretic Therapy for the Treatment of Edema in Adults with Heart Failure or Chronic Kidney Disease Globe Newswire 6:30 AM

-- June 23, 2026 --

MannKind Awarded Breakthrough T1D Grant to Support Advancement of INHALE-1ST Pediatric Trial of Afrezza in Youth with Newly-Diagnosed T1D Globe Newswire 9:00 AM

-- June 5, 2026 --

Data at ADA 2026 Highlights Key Findings from Clinical and Real-World Studies of MannKind's Afrezza (Inhaled Insulin) Across Pediatric Care, Pregnancy, and Use with Automated Insulin Delivery (AID) Systems Globe Newswire 7:35 PM

-- June 3, 2026 --

MannKind Enters Data-Rich Development Period with Completion of Randomization in Phase 1b INFLO-1 Study and Enrollment of First Patient in Phase 2 INFLO-2 Trial for Nintedanib DPI in Patients with IPF Globe Newswire 6:05 AM

-- May 29, 2026 --

MannKind to Host Conference Call Today to Discuss Afrezza Pediatric Approval Globe Newswire 2:00 PM
MannKind Announces FDA Approval of Afrezza, the First and Only Inhaled Mealtime Insulin for Use in Children and Adolescents Aged 6 and Older Living with Diabetes Globe Newswire 12:30 PM

-- May 27, 2026 --

MannKind to Present at Jefferies Global Healthcare Conference Globe Newswire 4:00 PM
MannKind to Showcase New Data at ADA 2026 Advancing Understanding of Inhaled Insulin (Afrezza) in Pediatric Care, Pregnancy and Use with Automated Insulin Delivery (AID) Systems Globe Newswire 9:05 AM

-- May 6, 2026 --

MannKind Reports First Quarter 2026 Financial Results and Provides Business Update Globe Newswire 4:01 PM
MannKind Announces Ralinepag Dry Powder Inhalation (DPI) Program to be Pursued for Pulmonary Hypertension and Fibrotic Lung Diseases Globe Newswire 6:30 AM

-- April 29, 2026 --

MannKind to Report First Quarter 2026 Financial Results on May 6, 2026 Globe Newswire 4:01 PM
Market Data Delayed 15 Minutes